Click on the “Search Now” button to search for research studies enrolling people like you. Need help getting started? Click on “Tips for Searching Studies” to find resources and assistance to help you find studies.

Search Results: (30 results)

1 through 30 of 93
Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib
Treatment:

Colorectal, Pancreatic

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib

This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized).

Chemotherapy drugs, such as liposomal irinotecan and fluorouracil damage cancer cells. Targeted therapies such as rucaparib, can keep cancer cells from being able to repair damage.

This study will look at how the targeted therapy rucaparib works with chemotherapy in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer. The study will measure the best dose and look at sides effects with this combination of drugs. 

More info
Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

 

This anonymous survey is being conducted by researchers at the National Human Genome Research Institute of the National Institutes of Health, in collaboration with Facing Our Risk of Cancer Empowered (FORCE). The goal of this survey is to help researchers understand the caregiving experiences of families affected by hereditary cancer. By sharing your experience with us, you can help us develop more resources to improve the experience of future family caregivers. 

Click here to take the survey. 

More info
Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
Treatment:

Breast, Ovarian, Pancreatic, Prostate

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes.

More info
TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency
Treatment:

Prostate

TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

The TALAPRO-2 study is assessing whether the study drug is safe and effective when given in combination with enzalutamide as a treatment option for men with metastatic castration-resistant prostate cancer and DDR deficiency.

More info
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor
Treatment:

Colorectal, Endometrial, Pancreatic

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-(L)1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-(L)1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

More info
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)
Treatment:

Colorectal

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself.

More info
Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome
Prevention:

Colorectal

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

This study will look at how well atorvastatin (a common cholesterol lowering agent) works with or without aspirin (a nonsteroidal anti-inflammatory drug) in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

More info
Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
Treatment:

Breast

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

More info
Men at High Genetic Risk for Prostate Cancer
Prevention:

Prostate

Men at High Genetic Risk for Prostate Cancer

The National Cancer Institute recently opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, CHEK2, PALB2, RAD51C RAD51D, BRIP1, FANCA. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.

More info
Breast and Ovarian Cancer Education Research for African American/Black and Latina Women
Prevention:

Breast

Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer

Researchers are conducting a study to test how well education materials increase use knowledge about hereditary cancer risk. Participants will watch 90 minutes of educational videos and complete 2 short surveys. In all, this will take approximately 3 hours to complete over a two-week period. Everything will be completed over the phone or online. Compensation will be provided for participation.

More info
Blood Markers of Early Pancreas Cancer
Prevention:

Pancreatic

Blood Markers of Early Pancreas Cancer

The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

More info
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Prevention:

Ovarian

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also exam various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

More info
Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
Treatment:

Pancreatic

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.

  • Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
  • Immunotherapy such as dostarlimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. 
More info
AMPLIFY: a new online weight loss study specifically for cancer survivors!
Quality of Life:

Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor

AMPLIFY: a new online weight loss study specifically for cancer survivors!

AMPLIFY is a nation-wide, web-based diet and exercise study recruiting overweight survivors of early stage breast, prostate, ovarian, renal, colorectal and endometrial cancer and multiple myeloma. This study is enrolling qualified cancer survivors age 50 and older who are interested in becoming more active, eating better and losing weight.

More info
Developing a Test for the Detection of Ovarian Cancer
Prevention:

Ovarian

Developing a Test for the Detection of Ovarian Cancer

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

More info
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis.

The PROMISE team is studying how these mutations affect patient outcomes.

More info
Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Treatment:

Colorectal

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.

More info
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
Treatment:

Breast

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

This study will look at how people with advanced triple-negative breast cancer (TNBC) respond to different combinations of drugs. During an initial study period participants will receive a combination of chemotherapy and immunotherapy drugs. Participants with stable cancer or an improvement will be able to continue with the study. Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead immunotherapy plus a type of targeted therapy known as a PARP inhibitor during the follow-up period.  

More info
TALAVE: Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Treatment:

Breast

TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

TALAVE is a study for patients who have advanced or metastatic breast cancer that will not be cured by treatment with surgery or radiotherapy, and either have a BRCA1/2 mutation (germline or somatic) or have triple negative breast cancer who are not known to have a BRCA1/2 mutation. The goal of TALAVE is to look at whether giving talazoparib alone followed by talazoparib with avelumab is a safe and effective treatment for advanced breast cancer.

More info
COVID-19 Breast Cancer Care Survey

COVID-19 Breast Cancer Care Survey

The purpose of this research study is to learn about how the COVID-19 pandemic has affected cancer care and quality of life in breast cancer survivors. Participants will complete an online survey and some women will be invited to participate in an online interview to learn more about their cancer treatment experiences during the pandemic.

More info
Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation
Prevention:

Pancreatic

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

More info
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
Prevention:

Colorectal

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body.

More info
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Treatment:

Pancreatic

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.

More info
Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations
Prevention:

Breast, Ovarian, Pancreatic, Prostate

Research Study to Help Improve Family Communication About Inherited Mutations

The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to: brcashare@osumc.edu.

More info
Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Treatment:

Breast

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC.

More info
Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

The purpose of this study is to compare the effectiveness of using a combination of the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy lenvatinib (Lenvima) in women with Stage III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment

More info
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer
Treatment:

Endometrial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High.

More info
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This study will look at how well PARP inhibitor olaparib works in treating women or men who have been diagnosed with biliary tract (bile duct) cancer that has metastasized to other places in the body and who also have DNA repair gene mutations that give them a higher risk of certain cancers.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

More info
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer or Checkpoint Inhibitor Relapsed Tumors

A Study of EDP1503 in Patients With Colorectal or Triple Negative Breast Cancer or Cancer That Came Back After Treatment with a Checkpoint Inhibitor

Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients. 

More info
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families
Prevention:

Ovarian

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. 

More info
Additional Results on Clinicaltrials.gov
1000 results
Clinical Trial Official Title
NCT04703920 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT04315233 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT03187028 Diet and Exercise After Pancreatic Cancer
NCT04117087 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
NCT03929029 Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
NCT04655157 Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
NCT03272464 INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NCT03104439 Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT04598009 Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04589832 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
NCT03520790 Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
NCT04592861 Carbon Ion RT for Locally Advanced Pancreatic Cancer
NCT02870244 Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT04024878 NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT03835819 A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT04996823 Axitinib + Ipilimumab in Advanced Melanoma
NCT04339140 Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT04611568 War on Melanoma™ Public Health & Education Campaign
NCT04552223 Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
NCT02482532 Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
NCT04594187 Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT04581382 Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
NCT03950635 Dietary Intervention in Patients With a History of Melanoma
NCT04930991 High Dose Omeprazole in Patients With Pancreatic Cancer
NCT03311308 A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT04464759 A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
NCT03757689 Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
NCT02706353 APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
NCT04526730 Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
NCT03958383 IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
NCT03935256 Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
NCT03341143 Fecal Microbiota Transplant (FMT) in Melanoma Patients
NCT03765229 An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
NCT03092453 Dendritic Cell Vaccination in Patients With Advanced Melanoma
NCT03743766 Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT03842943 Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT04493203 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT04688658 Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT04633902 Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
NCT04048278 Lidocaine Infusion in Pancreatic Cancer
NCT04513028 Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
NCT03712904 Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
NCT03925350 Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
NCT03246074 Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
NCT03646617 Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT04062032 Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
NCT01972919 Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer
NCT04129515 NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
NCT03957551 Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NCT04139902 Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
NCT04476537 RNA Precision Oncology in Advanced Pancreatic Cancer
NCT03501368 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
NCT04041128 PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
NCT04177810 Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
NCT03949517 A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy
NCT03809078 A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
NCT04318717 Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
NCT04187833 Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
NCT02041936 Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System
NCT04193904 A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
NCT03492164 In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
NCT04930159 Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT03439033 Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04935229 Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
NCT03699319 CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT04927013 Connecting Families to Overcome Ovarian Cancer
NCT04025229 High Intensity Interval Training in Endometrial Cancer
NCT03519308 A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
NCT04458402 Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT04390880 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
NCT03322995 Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
NCT04386993 De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT03287271 ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NCT04473833 Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT04608409 Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
NCT04720417 Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
NCT04364230 Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma
NCT04427306 Neoadjuvant T-VEC in High Risk Early Melanoma
NCT03932409 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03532139 Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT04941378 A Pilot, Single Dose, Open-Label Study of OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer -Comparing Camera Imaging Systems
NCT03801915 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
NCT04377087 Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
NCT03086642 Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
NCT02658565 Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation
NCT03385486 Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
NCT03232164 PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
NCT02451982 Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer
NCT02672098 Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
NCT03206645 PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
NCT03467516 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
NCT05050006 ITIL-168 in Advanced Melanoma
NCT03617328 Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
NCT03769766 Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03541928 Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
NCT03674814 Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT04700332 PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
NCT03734692 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT02128100 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
NCT02816021 Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
NCT04011410 Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
NCT00969111 Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT02282137 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT03617679 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
NCT03783325 Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma
NCT04179968 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
NCT03743298 Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
NCT03262103 Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
NCT04144127 Prostate Cancer Soccer
NCT03991130 High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
NCT04528199 [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
NCT03903640 Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
NCT04706962 TH1902 in Patients With Advanced Solid Tumors
NCT04741997 Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT03955978 TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT03822871 A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
NCT04562129 IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT02231775 Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
NCT04665947 First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04830124 Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
NCT03679260 Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance
NCT03223779 Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT04457089 Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
NCT02331134 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
NCT04266392 Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
NCT04936334 The Role of 68Ga-PSMA-11 PET in Surgery Guidance in Prostate Cancer
NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04588025 Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04082962 Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
NCT03694834 Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
NCT04635059 Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
NCT03384836 Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
NCT04842890 Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
NCT04116775 Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT04552509 TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT04727736 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT04349501 Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT04389918 Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer
NCT04167969 The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
NCT04037358 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
NCT03665922 Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer
NCT03392181 PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
NCT03971591 Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT03275857 Cisplatin in Castration Resistant Prostate Cancer
NCT04298983 Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
NCT04883775 Study of a New Technique for Imaging Pancreatic Cancer
NCT03999151 Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)
NCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT04147806 A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
NCT03585660 Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
NCT04264208 HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
NCT03315871 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
NCT04396808 Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT03730948 DC Vaccine in Colorectal Cancer
NCT03556904 FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
NCT04301414 Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
NCT02016248 Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer
NCT04904120 Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
NCT03800784 Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT03663218 PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)
NCT03600350 pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
NCT03585114 Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
NCT03619655 Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
NCT03753243 Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
NCT03712371 Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients
NCT03793543 Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
NCT02933255 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
NCT03187951 PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer
NCT03264404 Azacitidine and Pembrolizumab in Pancreatic Cancer
NCT04542291 Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
NCT04422132 Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
NCT03180398 Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT02600156 Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
NCT04360330 SABER Study for Selected Early Stage Breast Cancer
NCT04556045 Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer
NCT03495427 PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT02526368 Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT01607008 MRI for Assessing Prostate Cancer Response
NCT04737109 Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
NCT02946996 Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT04039230 Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT02382549 A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
NCT02290366 Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer
NCT03959891 AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
NCT03087903 A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA
NCT03349463 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
NCT03300505 ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
NCT02926729 Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT03553602 BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT04401995 Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab
NCT04220983 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
NCT04536077 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
NCT02362451 Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
NCT04086966 PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
NCT03833921 Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT03861975 Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT04899921 Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
NCT04561297 Assessing the Utility of Tissue Dielectric Constant (TDC) Measurements to Differentiate Breast Cancer From Healthy Breasts
NCT01088789 A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
NCT00588185 [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT02999477 A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT03486821 Ultra-hypofractionated Radiation in Prostate Cancer
NCT04454450 Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer
NCT04206319 Radium-223 in Biochemically Recurrent Prostate Cancer
NCT04743999 Evaluation of Quality of Life Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
NCT04670068 Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT03652428 Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT03769155 VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
NCT04038489 COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
NCT02420977 Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
NCT04066725 Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
NCT04502602 Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
NCT05021172 Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults
NCT03765983 GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT02902484 Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
NCT03649321 Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer
NCT04651452 Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT04158635 Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
NCT03130439 Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
NCT02040610 Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
NCT04129216 The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
NCT04986423 ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT03332589 E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
NCT03763838 Acupressure for Fatigue in Ovarian Cancer Survivors
NCT04253262 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
NCT02176161 Metformin Prostate Cancer Adjuvant Trial
NCT04132505 Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
NCT04109729 Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT04883814 18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04477512 Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
NCT02850939 Improving Adherence to EHT Among Breast Cancer Patients
NCT03564782 Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
NCT03212170 FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
NCT03761706 Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT04158245 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
NCT03620019 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
NCT03248570 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
NCT04420702 Diffusion Basis Spectrum Imaging of the Prostate
NCT04786600 A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
NCT04270149 Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT03965481 PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
NCT04483414 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
NCT04095689 Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
NCT04228055 Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)
NCT02391025 Gallium-68 Citrate PET Used in Prostate Cancer
NCT05025735 Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
NCT03292874 High Resolution MRI Study for Prostate Cancer
NCT01581749 Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT02515513 The Role of Muscle Cachexia in Pancreatic Cancer
NCT03668431 Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
NCT04450264 Increasing African Immigrant Women's Participation in Breast Cancer Screening
NCT02564848 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT03123978 Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
NCT04763174 An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)
NCT03312972 Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
NCT03237572 Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
NCT03742245 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT03366844 Breast Cancer Study of Preoperative Pembrolizumab + Radiation
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT02807805 Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
NCT04166435 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
NCT04336397 Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT02643667 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
NCT03694756 TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT03068624 Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
NCT04192071 Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT03641755 Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT03225547 Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
NCT04614363 68 Ga-PSMA for High Risk Prostate Cancer
NCT04282967 Streaming Web-based Exercise At Home: A Pilot Study
NCT01952730 GVAX for Colorectal Cancer
NCT03747042 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
NCT00734838 Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy
NCT05052723 Cabozantinib and Pembrolizumab in Metastatic Pancreas
NCT04768426 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT03190265 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
NCT04841148 Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04474184 Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
NCT03276832 Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
NCT03990896 Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT04892914 Embr Thermal Device for Hot Flash Management in Prostate Cancer
NCT02956473 Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
NCT00474604 Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants
NCT03109041 Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
NCT04262180 Physical Activity Promotion for Breast and Endometrial Cancer Survivors
NCT03930797 Coping Together After Breast Cancer
NCT04013568 Exercise Programming in Breast Cancer Patients
NCT03496805 Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
NCT03643861 RAD 1802: Pilot Trial of LINAC Based Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT03473639 A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT03253744 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
NCT03256201 Exercise and Nutrition to Improve Pancreatic Outcomes
NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT04628988 A Study of CC-90011 and Comparators in Participants With Prostate Cancer
NCT04272801 Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer
NCT03933670 Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT03543969 Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT04141995 FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NCT04542135 Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT04770714 Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients
NCT04508764 Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome
NCT00703105 Ovarian Dendritic Cell Vaccine Trial
NCT04493034 Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
NCT03956056 Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
NCT04594473 A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors
NCT04040569 Dose Escalation Study of Single Fraction Early Stage Breast Cancer
NCT03980509 A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors
NCT04667481 Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
NCT04106609 Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients
NCT03413332 Web-Based Communication Education for Breast Cancer Survivorship Care
NCT04532177 Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
NCT04454528 BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer
NCT03400215 Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT04849364 Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT03324425 Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
NCT03770598 Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients
NCT04197999 A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
NCT03820141 Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT04266431 EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
NCT04691999 The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer
NCT03750240 Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
NCT02035787 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
NCT03650803 Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer
NCT04354675 Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer
NCT04690855 A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT03122444 Imipramine on ER+ve and Triple Negative Breast Cancer
NCT04997018 A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
NCT04633252 Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT03304587 Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
NCT03916068 Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy
NCT03712813 Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
NCT04292847 LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT03822494 CyberKnife Dose Escalation Prostate Cancer Trial
NCT03964337 Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
NCT04805333 Phase 1 Dose Escalation of ArtemiCoffee
NCT03998618 Telephone Support for Metastatic Breast Cancer Patients
NCT04495257 A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT04106245 Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer
NCT02958774 Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT04763980 Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer
NCT04299620 Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
NCT03632941 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03413995 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
NCT03824275 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
NCT03915548 Optimizing Functional Recovery of Breast Cancer Survivors
NCT02482376 Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
NCT02510456 Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging
NCT04373031 Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT02683824 Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
NCT02809690 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
NCT03802851 HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
NCT04562233 Breast Cancer and Resistance Exercise Program
NCT04337580 Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT03958721 Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
NCT04848337 Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT03796195 (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
NCT04243616 Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT02706561 Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
NCT04427527 Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT04170920 Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs
NCT04444622 Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT04137536 A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
NCT03808077 The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
NCT03007732 Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT03045289 A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer
NCT04364672 Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer
NCT02807597 Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT04857502 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
NCT03492671 Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT03436745 The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
NCT02666378 Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
NCT03873818 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT04458532 Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT03819387 A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
NCT01913106 HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT04216134 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
NCT04205786 Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer
NCT04332588 Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT03572387 A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
NCT04032080 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
NCT02732171 PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT03032406 CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT03933813 Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
NCT04331067 Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer
NCT04709276 A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
NCT04134208 An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
NCT03935308 Phase I Study MR-guided SBRT to PCa
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT04748042 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT03711890 Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT04450706 Functional Precision Oncology for Metastatic Breast Cancer
NCT02227654 Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors
NCT04083963 Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
NCT03546686 Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer
NCT04352439 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT04273555 Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
NCT04091750 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
NCT03962647 A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
NCT04751929 Abemaciclib With or Without Atezolizumab for mCRPC
NCT04672005 Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
NCT04352777 Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
NCT04846478 Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
NCT02716948 SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
NCT03233555 Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
NCT03125928 Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT04090528 pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03707184 Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
NCT03911453 Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
NCT04708860 Feasibility of Fasting & Exercise in Pts With HR+ MBC
NCT02935205 Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT02613650 A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
NCT03043794 Study of Stereotactic Radiotherapy for Breast Cancer
NCT04854434 A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT01980823 Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
NCT04176497 PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
NCT01653093 3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
NCT05010200 The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
NCT04573231 Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT04310826 Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
NCT03533946 Rucaparib in Nonmetastatic prOstAte With BRCAness
NCT04946214 A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients
NCT03726320 Trial of Community Health Worker-led Decision Coaching
NCT05011799 Health Education Intervention for Genetic Evaluation for Prostate Cancer Among African American Men, The Peer Genetic Study
NCT04725903 Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT02626507 Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT04645680 Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study
NCT04123704 Sitravatinib in Metastatic Breast Cancer
NCT03671811 Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
NCT04837118 Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
NCT03699995 MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT05014295 Patient Recall of Cancer Screening and Diagnosis
NCT03601923 Niraparib in Patients With Pancreatic Cancer
NCT04866810 The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04891068 BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT03847168 KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
NCT04409002 Niraparib + Dostarlimab + RT in Pancreatic Cancer
NCT03831698 Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
NCT02177292 High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
NCT03745872 SunSmart Intervention in Schools
NCT04491955 Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
NCT04134884 Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT03889795 Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
NCT04634539 Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
NCT03475004 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
NCT04697576 Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma
NCT04074720 Prospective Breast Cancer Biospecimen Collection
NCT02435472 Active Surveillance Exercise Clinical Trial
NCT01508390 Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
NCT03854903 WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
NCT03569280 Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
NCT04267796 Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
NCT04967196 Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
NCT03085043 Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
NCT03502330 APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
NCT04462406 Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT02176902 Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
NCT04535323 Treatment of Genitourinary Syndrome of Menopause After Breast Cancer With PRP
NCT01955460 Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
NCT04721886 Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT04245176 Genetic Testing for All Breast Cancer Patients (GET FACTS)
NCT04913064 Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
NCT04251416 A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04703426 Sargramostim (GM-CSF) + PD-1
NCT04119024 Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT05055843 Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
NCT02409316 [18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02642094 Aging Mammary Stem Cells and Breast Cancer Prevention
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients
NCT04375527 Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
NCT03021460 Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03945721 A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT03719131 Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT04013854 Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04784182 Anti-anxiety Biotics for Breast Cancer Survivors
NCT03026517 Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
NCT02070705 DCE MRI in Patients With Pancreatic Cancer
NCT03822312 A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
NCT03580499 Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
NCT04720209 Taking AIM at Breast Cancer
NCT02068586 Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
NCT04098081 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT04361162 Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
NCT03801369 Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT02652923 Contrast Ultrasound Detection of Sentinel Lymph Nodes
NCT03661424 BATs in Patients With Breast Cancer and Leptomeningeal Metastases
NCT03679559 Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
NCT04256941 Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT04886986 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC
NCT04896073 Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT03429907 An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
NCT03675893 Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
NCT02768766 Intermittent Selumetinib for Uveal Melanoma
NCT05036083 Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion
NCT04506567 Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT04123574 A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
NCT04180579 Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
NCT04207255 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
NCT03977233 Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT02600949 Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT02996825 Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
NCT02401347 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
NCT02942355 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT03785210 Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
NCT03181867 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT04978675 An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
NCT03657108 CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation
NCT03439735 Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT04336943 Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
NCT02823262 A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
NCT03703492 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
NCT04533763 Living WELL: A Web-Based Program for Ovarian Cancer Survivors
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04616534 Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT03650894 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT02965755 Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT02681549 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04620603 Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
NCT02090114 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT04486755 Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04397016 Cost Talk: Discussing Cancer Care Costs
NCT04457232 Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT03526432 Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03592771 THRIVE Breast Cancer App Study
NCT04822597 Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
NCT03729115 A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03149081 A "Window Trial" on Boswellia for Breast Cancer Primary Tumors
NCT03525262 Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
NCT04504331 Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
NCT04525183 REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
NCT04174352 FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT04024254 A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT03677739 Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
NCT02334579 Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
NCT03955627 REJOIN Trial for Older Breast Cancer Survivors
NCT03367247 BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
NCT03727789 CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
NCT03902951 Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
NCT03865212 Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
NCT05043532 Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer
NCT03485729 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
NCT03847311 Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
NCT03936478 Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT04896580 IIT2020-20-SHIRAZIP-WALK: Nature Walks
NCT04296942 BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
NCT03831711 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
NCT02064673 Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT03878849 Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
NCT02910700 Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
NCT03949270 Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer
NCT04386057 LY3214996 +/- HCQ in Pancreatic Cancer
NCT04102722 Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening
NCT04903249 A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation
NCT03579472 M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03173924 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
NCT03050060 Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
NCT04576247 Combined Modality Exercise and Appetite in Breast Cancer Survivors
NCT04457245 Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
NCT03407417 A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT04738292 Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
NCT04887805 Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
NCT01587352 Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
NCT03703063 Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
NCT04139993 A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug
NCT04365569 Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
NCT04923542 Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT04724499 Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT04265872 Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT04465253 Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema
NCT02793921 Exercise Program in Cancer and Cognition
NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging
NCT03789877 A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity
NCT02599662 Intraoperative Radiation Therapy for Resectable Pancreas Cancer
NCT03825289 Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT04115163 Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT04636710 Refining Local-Regional Therapy for IBC
NCT03292198 Subclinical Lymphedema Treatment Study
NCT03769415 Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT04116073 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
NCT04267887 Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
NCT02903160 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
NCT05054296 Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT03873805 PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
NCT03012230 Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
NCT03698370 Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
NCT03152786 Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
NCT04983342 Apollo Device for Metastatic Breast Cancer (MBC)
NCT04539808 NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
NCT04123470 A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
NCT03263429 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
NCT03787303 Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
NCT04279561 Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
NCT02598349 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT02204098 Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT04066361 OPTimizing Treatment Focused Genetic Testing IN Cancer
NCT04215029 Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
NCT04985565 Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
NCT03649841 Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
NCT04907968 Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer
NCT03543189 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT03975621 Nurse AMIE: Addressing Metastatic Individuals Everyday
NCT02106598 Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
NCT02905578 A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
NCT03987217 Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
NCT03175432 Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
NCT04888975 A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT04253483 Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04194554 A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT04106856 Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
NCT03458234 RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy
NCT03460067 Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT03725761 IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
NCT04493333 Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
NCT04668976 A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT04379414 YES Study - Newly Diagnosed/Metastatic Intervention
NCT03261323 Breast Reconstruction Following Breast Cancer in Very High Risk Patients
NCT04670445 Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Lung Cancer or Melanoma
NCT04587128 Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT01985828 CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT02824575 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT04596917 Music Listening as a Postanesthesia Care Unit (PACU) Nursing Intervention
NCT03741335 GET FIT Prostate: A Randomized Controlled Exercise Trial
NCT03285412 CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT01972867 Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT04356729 A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT04658849 Insulin Resistance Following ADT for Prostate CA
NCT03899987 Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
NCT04630769 FT516 and IL2 With Enoblituzumab for Ovarian Cancer
NCT04288336 Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
NCT04262518 Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients
NCT03440554 Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT04108858 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
NCT03581500 Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
NCT03987386 Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT04614194 Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT03772834 Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
NCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04406714 Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)
NCT04263025 AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT02858869 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
NCT03581136 Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
NCT02229084 Vaccination of High Risk Breast Cancer Patients
NCT04088708 Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT04727632 [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
NCT04560712 Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery
NCT04993677 A Study of SEA-CD40 Given With Other Drugs in Cancers
NCT03821792 Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
NCT04191421 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
NCT04947917 Axillary Lymph Node Tattoo Marking Study
NCT03856658 Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT03592264 This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
NCT03298087 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
NCT01755208 Light-Scattering Spectroscopy for Detection of Breast Cancer
NCT04300478 Appetite and Exercise in Breast Cancer Survivors
NCT04493060 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
NCT02538484 Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
NCT04777071 An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
NCT03414034 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04834154 Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients
NCT04318028 An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
NCT04159896 ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT04131946 Cancer Screening; Access; Awareness; Navigation
NCT02912312 Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT03964532 TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
NCT03503344 Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR)
NCT03685331 HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT03033225 Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
NCT04982536 Assessment of VMCore Biopsy Versus Standard of Care Biopsy
NCT04867603 Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
NCT03999515 Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
NCT03406858 Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03781154 Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
NCT04574401 A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy
NCT03269526 BATs Treatment for Pancreatic Cancer, Phase Ib/II
NCT02971748 Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
NCT03805594 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04762225 RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma
NCT04394676 The Impact of Low Pressure Pneumo in RARP II
NCT04656678 Preliminary Effectiveness of Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Intermediate Risk Prostate Cancer
NCT04583891 Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design
NCT04908254 A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema
NCT03751436 Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03606486 Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
NCT02400658 Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
NCT04477343 A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT02290834 Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT04233385 Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT03632798 Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
NCT03507725 Early Staged Consent Before Prostate Biopsy
NCT04150042 A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations
NCT04648904 Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT03575832 Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
NCT03190967 T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
NCT03955640 Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
NCT03608631 iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
NCT03995082 Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT03689699 Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
NCT04750473 Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
NCT03824652 WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT02307058 Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT04600336 Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
NCT04030559 Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT04305236 Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
NCT04871139 An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT04928820 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
NCT04120246 Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT03983577 Efficacy of Point Of Service Testing in MBC
NCT04521764 A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT04248257 Peer Support For Young Adult Women With High Breast Cancer Risk
NCT04166383 VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
NCT04049214 Perioperative Mindfulness Proposal
NCT03120624 VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
NCT04740034 A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
NCT03779867 Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants
NCT03387553 HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT04030507 Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04164069 Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT04577963 A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer
NCT05025059 Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
NCT04046887 Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
NCT03990610 An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT04715958 Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
NCT03012399 Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery
NCT03880422 Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NCT04169321 Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response in Melanoma or NSCLC Participants
NCT04050085 SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
NCT04693338 Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer
NCT03844750 Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
NCT03367572 Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT03366155 Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT03955991 VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
NCT04432727 Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.
NCT03812393 Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
NCT04717050 Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT03454529 The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer
NCT04512261 TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
NCT04849871 Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT02188745 ER Reactivation Therapy for Breast Cancer
NCT03620201 M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
NCT04781374 Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT04471974 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03941756 Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT03424850 Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
NCT04249622 Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
NCT04216251 PRevention Using EPA Against coloREctal Cancer
NCT04576871 Re-treatment 225Ac-J591 for mCRPC
NCT04190446 Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment
NCT02834975 Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
NCT03806738 Enhancing Shared Decision-Making in Breast Cancer
NCT03774472 Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT04207359 Effects of Creatine Supplementation in Breast Cancer Survivors
NCT04022772 Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
NCT03318900 T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
NCT04454086 Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors
NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT02957981 The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
NCT02436993 Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
NCT04259905 Pink Warrior 2: Teleconference-based Gaming Support
NCT03923504 Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx
NCT04108481 Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
NCT05011279 Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)
NCT04855552 Telehealth Weight Loss Program for Breast Cancer Survivors
NCT04049695 Improving Cognition After Cancer
NCT03344211 Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
NCT04875728 The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
NCT04890054 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT03641287 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
NCT03796559 Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT04524702 Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
NCT03796767 Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT04205903 Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT02754752 Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
NCT04719273 Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer
NCT04090567 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT04560439 Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors
NCT02515110 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT00625417 Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT04946864 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT03094052 Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
NCT02157051 Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT04499950 Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
NCT02276885 Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
NCT04216472 Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
NCT04673448 Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT03803553 Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT04562987 The Patterns of Activity and Cognition During Treatment (PACT) Study
NCT03554083 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
NCT03207529 Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
NCT04597151 Diet Education Program for Stage I-IV Colorectal Cancer Survivors
NCT03554044 T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast Cancer
NCT03106415 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT04592237 Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT04374747 Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT02760030 Fulvestrant or Aromatase Inhibitor and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT04428905 Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
NCT03535727 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT03101748 Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT04677816 Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT03657069 Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy
NCT04267939 ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
NCT03216421 Intraoperative Radiation Therapy (IORT) in DCIS
NCT04016376 Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
NCT04762979 Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT04843306 Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients
NCT04081389 Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
NCT04393831 Pelvic Fascia spARing Radical Prostatectomy TrIAL
NCT03844620 Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
NCT04796818 An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
NCT03999749 A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT04481113 Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
NCT04894994 FLX475 in Combination With Ipilimumab in Advanced Melanoma
NCT04484909 NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT04362839 Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
NCT04085510 Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT03572283 Bethanechol Prior to Pancreatic Surgery
NCT03872388 Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
NCT04575922 Nivolumab+Ipilimumab+RT in MSS mCRC
NCT04172597 A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
NCT04470843 Impact of Acetazolamide in Reducing Referred Postoperative Pain
NCT05001282 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
NCT04616183 LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT04085055 Fine Needle Biopsy of Solid Pancreatic Mass Lesions
NCT04017650 Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT03396926 Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03006302 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
NCT04116164 Safety and Targeting of Anti-hk2 Antibody in mCRPC
NCT03991962 Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT02912572 Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT04333706 A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT03704662 Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT03838367 Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
NCT03910387 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT03113617 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
NCT03087071 Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT04458168 Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living
NCT04248153 Optimal Timing of BR55 CEUS of the Ovaries
NCT04832763 Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer
NCT04875806 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NCT03493464 BR55 in Characterization of Ovarian Lesions
NCT02738606 Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
NCT03161431 SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
NCT04674852 Mayo Designed Soft Tissue Ultrasound-Detectable Marker
NCT04995094 Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
NCT04023110 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
NCT04599218 MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer
NCT04485767 RESIST-ADT (Androgen Deprivation Therapy)
NCT03567889 Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT02949284 Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT04777786 Early Rehabilitation for Breast Cancer - A Randomized Control Trial
NCT04815083 Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT04126070 Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT04586959 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT02946697 A Culturally Sensitive Social Support Intervention
NCT04763902 Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT04789486 Nano-SMART: Nanoparticles With MR Guided SBRT in NSCLC and Pancreatic Cancer
NCT04990609 Endoscopic Ultrasound Guided- Radiofrequency Ablation Pancreas Cancer Trial
NCT02672917 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT04782713 Smart Prostate Specific Antigen (PSA) Screening Study
NCT04927663 11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT02876107 Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
NCT04705363 A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT02927912 Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT03955510 Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis
NCT03640208 Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT04461509 High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
NCT04313114 The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT03550885 Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk
NCT04763824 KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice
NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT03768492 Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
NCT03345420 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT03436563 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
NCT04683315 PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT03737370 Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT03100461 Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations
NCT04915508 Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
NCT02020707 Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT04594772 Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT04711161 First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
NCT04550494 Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT03146962 High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
NCT03484299 Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT05055323 A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT03991741 Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
NCT04005690 Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
NCT04407247 Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03540017 HIPEC After Initial CRS in Patients Who Have Received NACT
NCT04750941 Study of Copanlisib and Ketogenic Diet
NCT03202316 Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT04398446 Effect of Hemp-CBD on Patients With CIPN
NCT04517643 TheraSphere® For Treatment of Metastases in Liver
NCT02452008 Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT03592888 DC Vaccine in Pancreatic Cancer
NCT04646434 Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy
NCT04861896 A Research Study for Latina Women With Breast Cancer
NCT04599140 SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT04631744 Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT03429244 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
NCT04033328 Study of ORIC-101 in Combination With Enzalutamide
NCT03796273 Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT03328026 Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat
NCT03701581 4-aminopyridine Treatment for Nerve Injury
NCT04584255 Niraparib + TSR042 In BRCA Mutated Breast Cancer
NCT03073785 Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
NCT04837209 Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT03885284 Study of Proton Therapy in Adjuvant Pancreatic Cancer
NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT03507608 Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
NCT03865875 Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
NCT04026763 MR/TRUS Fusion Guided Prostate Biopsy
NCT02335671 Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT04606914 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03732950 Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
NCT03851237 CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT04491591 Implementing BREASTChoice Into Practice
NCT04143516 Tissue Analysis After Thermal Ablation for Colon Cancer Liver Metastases Leading to Immediate Retreatment
NCT02095184 GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT04305145 Infliximab for Treatment of Ipilimumab Colitis
NCT03975491 The Exercise And Colorectal Cancer Treatment Trial
NCT03661047 OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
NCT03642067 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
NCT04514692 Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT03476681 QUILT-3.017: Study of NEO-201 in Solid Tumors
NCT02124421 HOT: HIPEC in Ovarian Cancer as Initial Treatment
NCT03008408 A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
NCT04985604 DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
NCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT03472586 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
NCT01794403 Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
NCT03421782 Fatigue Interventions in Cancer (Exercise Intervention)
NCT03428581 Preventing Lymphedema in Axillary Lymph Node Dissection
NCT01407263 Trial of Modifications to Radical Prostatectomy
NCT03419585 The "PC-LIGHT" Study
NCT03941743 Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
NCT03657641 Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT04234386 GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT04660929 CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT03446157 Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT04527900 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT04936243 TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)
NCT03327103 Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth
NCT03764137 Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
NCT03573648 Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT04440982 Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Receiving Neoadjuvant Therapy
NCT04906200 Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
NCT04261387 LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
NCT04862585 Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT03290677 Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT02012296 Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
NCT03784677 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
NCT03511690 Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment
NCT04009044 Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT04764292 Screening Contrast-Enhanced Mammography as an Alternative to MRI
NCT02891538 Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
NCT04197687 TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT05025748 Ask Questions (ASQ):Implementation of a Communication Intervention
NCT02415387 Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
NCT03658772 Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
NCT04329065 Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT05039801 IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT04925817 3D Ultrasound Microvessel Imaging for Breast Masses
NCT03630354 EXERCISING TOGETHER for Couples Coping With Cancer
NCT03711058 Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
NCT01719562 MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

Research Search Tool Sponsored By:

Supported by a cooperative agreement from the
Patient Centered Outcomes Research Institute: PCORI EAIN-00055

and by:

Eisai